Patents by Inventor Michael C. Jensen

Michael C. Jensen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11649288
    Abstract: Aspects of the invention described herein relate to synthetic compounds that are useful for targeting and labeling tumor cells so as to facilitate recognition by binding agents including Chimeric Antigen Receptor T cells (CAR T cells), which are administered to a subject by intravenous or locoregional administration. Several compositions and methods of making and using these compositions to treat or inhibit a disease in a subject are contemplated.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: May 16, 2023
    Assignee: Seattle Children's Hospital
    Inventors: Michael C. Jensen, James Matthaei
  • Publication number: 20230130938
    Abstract: Disclosed herein are methods of engineering a bi-specific T-cell expressing chimeric antigen receptors for promoting the in vivo expansion and activation of an effector cell and a second chimeric antigen receptor or TcR specific for a ligand on a tumor. Methods of administering to subjects in need, bi-specific chimeric antigen receptor bearing cells are also provided.
    Type: Application
    Filed: September 12, 2022
    Publication date: April 27, 2023
    Inventor: Michael C. Jensen
  • Publication number: 20230091447
    Abstract: Provided are methods for preventing or ameliorating toxicity caused by or due to a therapy, such as an immunotherapy or a cell therapy, by pre-emptive or early administration toxicity-targeting agent(s). In some embodiments, the therapy is a cell therapy in which the cells generally express recombinant receptors such as chimeric receptors, e.g., chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). Features of the methods, including the timing of the administration of the agents or treatments for toxicity, provide various advantages, such as lower toxicity while maintaining persistence and efficacy of the administered cells.
    Type: Application
    Filed: December 2, 2022
    Publication date: March 23, 2023
    Inventors: Michael C. Jensen, Rebecca Gardner
  • Publication number: 20230068879
    Abstract: Embodiments provided herein include methods and compositions comprising anti-dinitrophenol chimeric antigen receptors (CARs). Some embodiments include nucleic acids encoding such CARs, polypeptides encoded by such nucleic acids, cells comprising such nucleic acids or polypeptides, and methods utilizing such cells. Some embodiments also include the use of dinitrophenol (DNP) and derivatives thereof.
    Type: Application
    Filed: February 2, 2021
    Publication date: March 2, 2023
    Inventors: Michael C. Jensen, James F. Matthaei, Joseph K. Cheng
  • Publication number: 20220411805
    Abstract: Provided herein is a system for inducible expression of a chimeric antigen receptor in cells, such as mammalian cells.
    Type: Application
    Filed: June 20, 2022
    Publication date: December 29, 2022
    Inventors: Michael C. Jensen, Tracy Ooi, Jia Wei
  • Publication number: 20220380461
    Abstract: The present invention provides genetic tags operably linked to transgenes. The expression of the genetic tag allows identification, detection, selection, and ablation of cells expressing the transgene and the genetic tag. In some alternatives the genetically modified host cell comprises a transgene comprising a polynucleotide coding for a chimeric antigen receptor comprising a ligand binding domain, a polynucleotide comprising a spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain and a polynucleotide coding for a genetic tag.
    Type: Application
    Filed: July 15, 2022
    Publication date: December 1, 2022
    Inventors: Michael C. Jensen, Adam Johnson
  • Publication number: 20220372140
    Abstract: Aspects of the invention described herein, concern approaches to make genetically modified T-cells comprising a chimeric antigen receptor for human therapy. In some alternatives, the methods utilize a selection and/or isolation of CD4+ and/or CD8+ T-cells from a mixed T-cell population, such as, peripheral blood or apheresis derived mononuclear cells. Once selected/isolated, the CD4+ and/or CD8+ T-cells are then activated, genetically modified, and propagated, preferably, in separate or isolated cultures in the presence of one or more cytokines, which support survival, engraftment and/or proliferation of the cells, as well as, preferably promoting or inducing the retention of cell surface receptors, such as CD62L, CD28, and/or CD27.
    Type: Application
    Filed: April 21, 2022
    Publication date: November 24, 2022
    Inventor: Michael C. Jensen
  • Patent number: 11458167
    Abstract: Disclosed herein are methods of engineering a bi-specific T-cell expressing chimeric antigen receptors for promoting the in vivo expansion and activation of an effector cell and a second chimeric antigen receptor or TcR specific for a ligand on a tumor. Methods of administering to subjects in need, bi-specific chimeric antigen receptor bearing cells are also provided.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: October 4, 2022
    Assignee: Seattle Children's Hospital
    Inventor: Michael C. Jensen
  • Publication number: 20220257652
    Abstract: The present disclosure relates to methods of treating a patient with a cancer by administering to the patient a composition comprising CAR T cells wherein the CAR T cells comprise a CAR and the CAR comprises an E2 anti-fluorescein antibody fragment, and administering to the patient a small molecule linked to a targeting moiety by a linker. The disclosure also relates to compositions for use in such methods.
    Type: Application
    Filed: January 27, 2022
    Publication date: August 18, 2022
    Inventors: Michael C. Jensen, James Matthaei
  • Patent number: 11414486
    Abstract: The present invention provides genetic tags operably linked to transgenes. The expression of the genetic tag allows identification, detection, selection, and ablation of cells expressing the transgene and the genetic tag. In some alternatives the genetically modified host cell comprises a transgene comprising a polynucleotide coding for a chimeric antigen receptor comprising a ligand binding domain, a polynucleotide comprising a spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain and a polynucleotide coding for a genetic tag.
    Type: Grant
    Filed: February 19, 2020
    Date of Patent: August 16, 2022
    Assignee: Seattle Children's Hospital
    Inventors: Michael C. Jensen, Adam Johnson
  • Patent number: 11408005
    Abstract: Provided herein is a system for inducible expression of a chimeric antigen receptor in cells, such as mammalian cells.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: August 9, 2022
    Assignee: Seattle Children's Hospital
    Inventors: Michael C. Jensen, Tracy Ooi, Jia Wei
  • Publication number: 20220195441
    Abstract: Some embodiments of the methods and compositions provided herein include chimeric antigen receptors (CAR)s which specifically bind to an epitope of CD33, such as an epitope encoded by exon 2 of CD33. Some embodiments include the use of such CARs for effective and safe therapies for myeloid leukemias, such as acute myeloid leukemia and chronic myeloid leukemia.
    Type: Application
    Filed: April 21, 2020
    Publication date: June 23, 2022
    Inventors: Michael C. Jensen, Soheil Meshinchi
  • Publication number: 20220193136
    Abstract: A CD19-OR-CD20 chimeric antigen receptor (CAR) protein construct is provided. Also provided are nucleic acids encoding the CD19-OR-CD20 CAR; and methods of use, e.g. in the treatment of B cell malignancies. The CD19-OR-CD20 CAR of the invention is a bispecific CAR that can trigger T-cell activation upon detection of either CD19 or CD20 (or both). It is a single molecule that confers two-input recognition capability upon human T cells engineered to stably express this CAR.
    Type: Application
    Filed: January 5, 2022
    Publication date: June 23, 2022
    Inventors: Yvonne Y. CHEN, Eugenia ZAH, Michael C. JENSEN
  • Publication number: 20220125841
    Abstract: Some embodiments of the methods and compositions provided herein relate to modulating signaling of anti-hapten CAR T cells, such as anti-fluorescein CAR T cells, by the use or administration of an unconjugated hapten, such as unconjugated fluorescein or a salt or derivative thereof.
    Type: Application
    Filed: March 11, 2020
    Publication date: April 28, 2022
    Inventors: Michael C. Jensen, James Matthaei
  • Patent number: 11311576
    Abstract: The present disclosure relates to methods of treating a patient with a cancer by administering to the patient a composition comprising CAR T cells wherein the CAR T cells comprise a CAR and the CAR comprises an E2 anti-fluorescein antibody fragment, and administering to the patient a small molecule linked to a targeting moiety by a linker. The disclosure also relates to compositions for use in such methods.
    Type: Grant
    Filed: January 22, 2019
    Date of Patent: April 26, 2022
    Assignee: Seattle Children's Hospital
    Inventors: Michael C. Jensen, James Matthaei
  • Publication number: 20220096549
    Abstract: Some embodiments of the methods and compositions provided herein relate to chimeric cytokine receptors. In some embodiments, a chimeric cytokine receptor can include an IL-7 tethered to an extracellular IL-7 receptor domain, and an intracellular IL-21 receptor domain linked to the extracellular IL-7 receptor domain. In some embodiments, a T cell containing a chimeric cytokine receptor can be readily activated and/or expanded in the absence of an exogenous cytokine.
    Type: Application
    Filed: February 6, 2020
    Publication date: March 31, 2022
    Inventors: Michael C. Jensen, Christopher P. Saxby
  • Publication number: 20220064292
    Abstract: The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor under the control of an inducible promoter. In some alternatives the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a chimeric antigen receptor comprising a ligand binding domain, a polynucleotide comprising a spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain under the control of a drug inducible promoter. Controlling the expression of the chimeric receptor provides for the ability to turn expression on and off depending on the status of the patient.
    Type: Application
    Filed: September 10, 2021
    Publication date: March 3, 2022
    Inventor: Michael C. Jensen
  • Patent number: 11253546
    Abstract: A CD19-OR-CD20 chimeric antigen receptor (CAR) protein construct is provided. Also provided are nucleic acids encoding the CD19-OR-CD20 CAR; and methods of use, e.g. in the treatment of B cell malignancies. The CD19-OR-CD20 CAR of the invention is a bispecific CAR that can trigger T-cell activation upon detection of either CD19 or CD20 (or both). It is a single molecule that confers two-input recognition capability upon human T cells engineered to stably express this CAR.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: February 22, 2022
    Assignees: The Regents of the University of California, Seattle Children's Hospital
    Inventors: Yvonne Y. Chen, Eugenia Zah, Michael C. Jensen
  • Publication number: 20220041986
    Abstract: A non-immunogenic selection epitope may be generated by removing certain amino acid sequences of the protein. For example, a gene encoding a truncated human epidermal growth factor receptor polypeptide (EGFRt) that lacks the membrane distal EGF-binding domain and the cytoplasmic signaling tail, but retains an extracellular epitope recognized by an anti-EGFR antibody is provided. Cells may be genetically modified to express EGFRt and then purified without the immunoactivity that would accompany the use of full-length EGFR immunoactivity. Through flow cytometric analysis, EGFRt was successfully utilized as an in vivo tracking marker for genetically modified human T cell engraftment in mice. Furthermore, EGFRt was demonstrated to have cellular depletion potential through cetuximab mediated antibody dependent cellular cytotoxicity (ADCC) pathways.
    Type: Application
    Filed: October 22, 2021
    Publication date: February 10, 2022
    Inventor: Michael C. Jensen
  • Publication number: 20210371517
    Abstract: The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor. In some alternatives the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a ligand binding domain, a polynucleotide comprising a customized spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain. In some alternatives, the ligand binding domains binds to CD171.
    Type: Application
    Filed: November 13, 2020
    Publication date: December 2, 2021
    Inventor: Michael C. Jensen